Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1): Patent #: 8,846,891

Research output: Patent

Standard

Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1) : Patent #: 8,846,891. / Prentø, Jannick Cornelius (Inventor); Gottwein, Judith Margarete (Inventor); Scheel, Troels Kasper Hoyer (Inventor); Bukh, Jens (Inventor); Jensen, Tanja Bertelsen (Inventor).

Patent No.: WO2010/022727. Sep 30, 2014.

Research output: Patent

Harvard

Prentø, JC, Gottwein, JM, Scheel, TKH, Bukh, J & Jensen, TB Sep. 30 2014, Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1): Patent #: 8,846,891, Patent No. WO2010/022727.

APA

Prentø, J. C., Gottwein, J. M., Scheel, T. K. H., Bukh, J., & Jensen, T. B. (2014). Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1): Patent #: 8,846,891. (Patent No. WO2010/022727).

Vancouver

Prentø JC, Gottwein JM, Scheel TKH, Bukh J, Jensen TB, inventors. Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1): Patent #: 8,846,891. WO2010/022727. 2014 Sep 30.

Author

Prentø, Jannick Cornelius (Inventor) ; Gottwein, Judith Margarete (Inventor) ; Scheel, Troels Kasper Hoyer (Inventor) ; Bukh, Jens (Inventor) ; Jensen, Tanja Bertelsen (Inventor). / Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1) : Patent #: 8,846,891. Patent No.: WO2010/022727. Sep 30, 2014.

Bibtex

@misc{1d24a705c00447d3bebba2f0b2dc2a4e,
title = "Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1): Patent #: 8,846,891",
abstract = "The present inventors used the previously developed H77/JFH 1.sub.T27OOC,A4O8OT (1a/2a), J4/JFH .sub.1T2996C,A4827T,.DELTA.HVRI (1b/2a), J6/JFH .sub.1.DELTA.HVRI (2a/2a), J8/JFH 1.sub..DELTA.HVRI (2b/2a), S52/JFH 1.sub.T27i8G,.tau.7i6oc (3a/2a), SA13/JFH 1.sub.C34O5G,A3696G (5a/2a) and HK6a/JFH 1T.sub.1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH 1 (genotype 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH 1.sub.T27OOC,A4O8OT,.DELTA.HVR1 (1a/2a), J8/JFH .sub.1.DELTA.HVR1 (2b/2a), S52/JFH 1.sub.T2718G,T716OC,.DELTA.HVR1 (3a/2a) and J4/JFH 1.sub.T2996C,A4827T,.DELTA.HVR1 (1b/2a) to the HVR1 deletion.",
author = "Prent{\o}, {Jannick Cornelius} and Gottwein, {Judith Margarete} and Scheel, {Troels Kasper Hoyer} and Jens Bukh and Jensen, {Tanja Bertelsen}",
year = "2014",
month = sep,
day = "30",
language = "English",
type = "Patent",
note = "WO2010/022727; C07H 21/04 (20060101); C07H 21/02 (20060101)",

}

RIS

TY - PAT

T1 - Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1)

T2 - Patent #: 8,846,891

AU - Prentø, Jannick Cornelius

AU - Gottwein, Judith Margarete

AU - Scheel, Troels Kasper Hoyer

AU - Bukh, Jens

AU - Jensen, Tanja Bertelsen

PY - 2014/9/30

Y1 - 2014/9/30

N2 - The present inventors used the previously developed H77/JFH 1.sub.T27OOC,A4O8OT (1a/2a), J4/JFH .sub.1T2996C,A4827T,.DELTA.HVRI (1b/2a), J6/JFH .sub.1.DELTA.HVRI (2a/2a), J8/JFH 1.sub..DELTA.HVRI (2b/2a), S52/JFH 1.sub.T27i8G,.tau.7i6oc (3a/2a), SA13/JFH 1.sub.C34O5G,A3696G (5a/2a) and HK6a/JFH 1T.sub.1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH 1 (genotype 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH 1.sub.T27OOC,A4O8OT,.DELTA.HVR1 (1a/2a), J8/JFH .sub.1.DELTA.HVR1 (2b/2a), S52/JFH 1.sub.T2718G,T716OC,.DELTA.HVR1 (3a/2a) and J4/JFH 1.sub.T2996C,A4827T,.DELTA.HVR1 (1b/2a) to the HVR1 deletion.

AB - The present inventors used the previously developed H77/JFH 1.sub.T27OOC,A4O8OT (1a/2a), J4/JFH .sub.1T2996C,A4827T,.DELTA.HVRI (1b/2a), J6/JFH .sub.1.DELTA.HVRI (2a/2a), J8/JFH 1.sub..DELTA.HVRI (2b/2a), S52/JFH 1.sub.T27i8G,.tau.7i6oc (3a/2a), SA13/JFH 1.sub.C34O5G,A3696G (5a/2a) and HK6a/JFH 1T.sub.1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH 1 (genotype 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH 1.sub.T27OOC,A4O8OT,.DELTA.HVR1 (1a/2a), J8/JFH .sub.1.DELTA.HVR1 (2b/2a), S52/JFH 1.sub.T2718G,T716OC,.DELTA.HVR1 (3a/2a) and J4/JFH 1.sub.T2996C,A4827T,.DELTA.HVR1 (1b/2a) to the HVR1 deletion.

M3 - Patent

M1 - WO2010/022727

Y2 - 2010/03/04

ER -

ID: 140391809